
The European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to Adverum Biotechnologies’ (NASDAQ:ADVM) lead drug ADVM-022 for the treatment of wet age-related macular degeneration (wet AMD).
A Phase 2 study in wet AMD is planned to investigate ADVM-022, expects dosing the first patient in the third quarter of 2022.